Can steroids be given to someone with herpes zoster?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Steroids in Herpes Zoster Management

Steroids can be given to patients with herpes zoster, but they provide only modest benefits for acute pain while offering no benefit for preventing postherpetic neuralgia, and should be used with caution in immunocompromised patients.

Evidence-Based Recommendations

Indications for Steroid Use

  • Steroids may provide modest benefits in reducing acute pain and improving quality of life during the acute phase of herpes zoster
  • Steroids do not prevent postherpetic neuralgia (PHN), which is the most concerning long-term complication 1
  • Steroids should always be given with concurrent antiviral therapy, never alone

Patient Selection

Steroids should be limited to:

  • Immunocompetent patients
  • Patients without contraindications to steroids (diabetes, hypertension, psychiatric disorders)
  • Patients with moderate to severe acute pain
  • Patients receiving concurrent antiviral therapy

Contraindications

Avoid steroids in patients with:

  • Immunocompromised status
  • Uncontrolled diabetes mellitus
  • Uncontrolled hypertension
  • Active psychiatric disorders
  • Patients receiving certain immunomodulatory therapies

Special Considerations

Immunocompromised Patients

For patients on immunomodulatory therapies or with immunocompromised status:

  • Prophylaxis against herpes zoster is recommended for patients on bortezomib-based regimens 2
  • Prophylactic antiviral therapy is recommended for all patients receiving protease inhibitor-based and antibody-based therapies 2
  • Herpes zoster prophylaxis is important with bortezomib and steroid combinations 2

Vaccination Strategies

  • Recombinant zoster vaccination (Shingrix) should be considered in all patients aged 50 or over receiving any immunomodulators or advanced therapies 2
  • Patients aged 18 and over starting JAK inhibitors should receive recombinant zoster vaccination 2
  • Herpes zoster vaccination may be considered in patients with autoimmune inflammatory rheumatic diseases, but only when less severely immunosuppressed 2

Treatment Protocol

Recommended Regimen

If steroids are used:

  • Prednisone 40-60 mg/day tapered over 3 weeks 3, 4
  • Must be combined with antiviral therapy (acyclovir 800 mg orally, five times daily for 7 days) 3
  • Initiate within 72 hours of rash onset for maximum benefit 5

Monitoring

  • Monitor for steroid-related adverse effects including:
    • Hyperglycemia
    • Hypertension
    • Mood changes
    • Secondary infections
    • Skin atrophy
  • Evaluate patients for development of bortezomib-related peripheral or autonomic neuropathy if applicable 2

Clinical Pearls and Pitfalls

Pearls

  • Early initiation of antivirals (within 72 hours of onset) is more important than steroids for reducing severity and duration of herpes zoster 5
  • Consider early initiation of anticonvulsants or tricyclic antidepressants in patients with high risk of postherpetic neuralgia 5

Pitfalls

  • Relying on steroids to prevent postherpetic neuralgia (they don't work for this purpose)
  • Using steroids without concurrent antiviral therapy
  • Using steroids in immunocompromised patients, which may increase risk of disseminated disease 4
  • Failing to recognize that JAK inhibitors may increase risk of herpes zoster (upadacitinib has shown increased rates of herpes zoster infection) 2

By following these evidence-based recommendations, clinicians can appropriately manage herpes zoster while minimizing risks associated with steroid therapy.

References

Research

Corticosteroids for preventing postherpetic neuralgia.

The Cochrane database of systematic reviews, 2010

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Oral corticosteroids for pain associated with herpes zoster.

The Annals of pharmacotherapy, 1998

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.